1. Reportlinker Adds Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
(News/Breaking News)

...  10.122 Progen 678 10.123 Protox Therapeutics 679  ...

2. Cyprotex Adds In Vitro Toxicology Services
(News/Breaking News)

... as Cyprotox(R). Supporting the new service is an additional 90 square metres of laboratory space at Cyprotex's Macclesfield, UK facility housing the latest technology in multi-parametric automated fluorescent ...

3. Protox Therapeutics Reports Positive Results for BPH Treatment
(Home Page/Home Page)

Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The ...

4. Protox Therapeutics Vital Phase 2b Results Coming Soon (PTXRF.PK / PRX:TSO)
(Home Page/Home Page)

Protox Therapeutics (PTXRF) uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. In Late December ...

5. BioMed Updates: ELTP.OB, SOMX, STEM, GERN, ASTM, VRTX, CYTR, IMUC.OB, JAV
(Home Page/Home Page)

... stock / 1.5M options New Report on Protox by Dundee Securites Ahead of Key Results (TSX: PRX.TO) (OTC: PTXRF.PK) / http://hub.tm/?kGFaK $CYTR / CytRx / FDA Lifts Clinical Hold / Will resume clinial ...

6. Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Unilife
(Home Page/Home Page)

... site in mid-April. Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) (click on preceding link for the Company's ProActive News Room landing page) applies genetic engineering techniques to create innovative, ...

7. Protox Therapeutics (OTC: PTXRF.PK) Presents Data, Awaits Key Results for PRX302
(Home Page/Home Page)

Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.  ...

8. FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
(Premium Content/Subscriber Only Content)

... groups of subjects, including: 1) a control group, 2) a group that will utilize ActiPatch Therapy, and 3) a group that will be given acetaminophen in the form of Tylenol. Protox Therapeutics (TSX: PRX.TO) ...

9. FDA Calendar Extreme Trades:10 Single Digit Stocks
(Home Page/Home Page)

... by Sandoz in the manufacturing process. On 9/8/09, Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) (US$0.58) announced that it has completed patient enrollment in a multi-center, double-blinded, placebo-controlled ...

10. FDA Calendar Extreme Trades: 85 Single Digit Stocks
(Premium Content/Subscriber Only Content)

... FDA decision on this sNDA.   71.) On 9/8/09, Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) (US$0.58) announced that it has completed patient enrollment in a multi-center, double-blinded, placebo-controlled ...

11. Protox Therapeutics: A Molecular Approach to Surgery
(Home Page/Home Page)

Protox Therapeutics (TSX: PRX.TO) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The Company’s clinical-stage ...

12. ProActive Capital Resources Group Is Pleased to Announce Client Participation in the 2010 OneMedForum
(News/Breaking News)

... DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending. DataTrak International, Inc. is presenting on Wednesday, January 13, 2010 at 9:45 AM. Mike Havrilla reports: ...